Paloma Wang

Ms. Wang’s experience (including her experience prior to joining Skadden) includes advising:

• Koolearn Technology Holding Limited (China) in its HK$1.6 billion initial public offering and listing on the Hong Kong Stock Exchange;
• Tianli Education International Holdings Limited in its initial public offering in Hong Kong;
• Innovent Biologics, Inc. in its US$421 million global offering and listing on the Hong Kong Stock Exchange;
• China Renaissance Holdings Limited in its US$350 million initial public offering and listing on the Hong Kong Stock Exchange;
• WuXi Biologics (Cayman) Inc. and G&C VII Limited in their respective capacity as the issuer and controlling shareholder in the approximately US$600 million placing of new shares and existing shares;
• Future Land Development Holdings Limited in its approximately US$200 million top-up share placing and issuance of approximately US$300 million convertible notes;
• WuXi Biologics Holdings Limited in the sale of its existing shares of WuXi Biologics (Cayman) Inc. for a consideration of approximately US$650 million;
• the underwriters in the approximately US$510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. on the Hong Kong Stock Exchange;
• Sinco Pharmaceuticals Holdings Limited in its global offering and initial public offering on the Hong Kong Stock Exchange;
• CGN Power Co. Ltd., China’s largest nuclear power producer, in its US$3.2 billion global offering and initial public offering on the Hong Kong Stock Exchange;
• Danone Asia Pte. Ltd. in its sale of Dumex Baby Food Co., Ltd. to Yashili International Holdings Limited and investment in China Mengniu Dairy Company Limited;
• Future Land Development Holdings Limited in its approximately US$265 million global offering and initial public offering on the Hong Kong Stock Exchange;
• Midas Holdings Limited, a Singapore-incorporated company, in its approximately US$150 million secondary listing on the Hong Kong Stock Exchange; and
• the underwriters/sponsors in the following transactions:
  • the US$285 million Hong Kong IPO of CStone Pharmaceuticals;
  • the US$510 million global offering and initial public offering of WuXi Biologics (Cayman) Inc. on the Hong Kong Stock Exchange;
  • the US$1.15 billion global offering and initial public offering of Dali Foods Group Company Limited on the Hong Kong Stock Exchange;
  • the US$203 million global offering and initial public offering of Guorui Properties Limited on the Hong Kong Stock Exchange;
  • the US$500 million global offering and initial public offering of H shares of China Machinery Engineering Corporation on the Hong Kong Stock Exchange;
  • the HK$1.3 billion global offering and initial public offering of Besunyen Holdings Company Limited on the Hong Kong Stock Exchange; and
  • the listing by way of introduction of China Animal Healthcare Ltd. on the Hong Kong Stock Exchange.

Ms. Wang joined Skadden in 2018 and prior to that worked in the Hong Kong office of another highly regarded global law firm as a partner in its capital markets practice. She is noted for her "distinguished leadership" by Asia Pacific Legal 500 2017.